Myomo, Inc. (MYO)
USD 4.88
(2.95%)
USD 4.88
(2.95%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 601.3 Thousand USD | 8.56% |
| 2022 | 553.9 Thousand USD | -24.64% |
| 2021 | 735 Thousand USD | 323.79% |
| 2020 | 173.43 Thousand USD | -93.46% |
| 2019 | 2.65 Million USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | -100.0% |
| 2016 | 5.45 Million USD | 166.19% |
| 2015 | 2.04 Million USD | 47.38% |
| 2014 | 1.39 Million USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 486.11 Thousand USD | -19.16% |
| 2024 Q2 | 363.93 Thousand USD | -25.13% |
| 2023 FY | 601.3 Thousand USD | 8.56% |
| 2023 Q4 | 601.3 Thousand USD | -15.22% |
| 2023 Q3 | 709.27 Thousand USD | 120.66% |
| 2023 Q2 | 321.44 Thousand USD | -27.73% |
| 2023 Q1 | 444.79 Thousand USD | -19.7% |
| 2022 Q3 | 662.28 Thousand USD | -13.47% |
| 2022 Q4 | 553.9 Thousand USD | -16.36% |
| 2022 FY | 553.9 Thousand USD | -24.64% |
| 2022 Q1 | 863.57 Thousand USD | 17.49% |
| 2022 Q2 | 765.42 Thousand USD | -11.37% |
| 2021 Q3 | 776.06 Thousand USD | -12.06% |
| 2021 Q2 | 882.51 Thousand USD | 4.0% |
| 2021 FY | 735 Thousand USD | 323.79% |
| 2021 Q1 | 848.56 Thousand USD | 389.27% |
| 2021 Q4 | 735 Thousand USD | -5.29% |
| 2020 Q3 | 78.04 Thousand USD | -92.74% |
| 2020 FY | 173.43 Thousand USD | -93.46% |
| 2020 Q4 | 173.43 Thousand USD | 122.23% |
| 2020 Q2 | 1.07 Million USD | -24.71% |
| 2020 Q1 | 1.42 Million USD | -46.19% |
| 2019 Q2 | - USD | 0.0% |
| 2019 Q3 | - USD | 0.0% |
| 2019 FY | 2.65 Million USD | 0.0% |
| 2019 Q4 | 2.65 Million USD | 0.0% |
| 2019 Q1 | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2017 Q3 | 1.89 Million USD | -7.01% |
| 2017 Q2 | 2.03 Million USD | -71.8% |
| 2017 FY | - USD | -100.0% |
| 2017 Q1 | 7.22 Million USD | 32.49% |
| 2017 Q4 | - USD | -100.0% |
| 2016 Q2 | 3.25 Million USD | 0.0% |
| 2016 FY | 5.45 Million USD | 166.19% |
| 2016 Q1 | - USD | -100.0% |
| 2016 Q4 | 5.45 Million USD | 0.0% |
| 2015 FY | 2.04 Million USD | 47.38% |
| 2015 Q4 | 2.04 Million USD | 0.0% |
| 2015 Q3 | 2.04 Million USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2014 FY | 1.39 Million USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Abbott Laboratories | 15.87 Billion USD | 99.996% |
| Allurion Technologies Inc. | 41.85 Million USD | 98.563% |
| Artivion, Inc. | 359.34 Million USD | 99.833% |
| Avanos Medical, Inc. | 209.1 Million USD | 99.712% |
| Butterfly Network, Inc. | 25.02 Million USD | 97.597% |
| Butterfly Network, Inc. | 25.02 Million USD | 97.597% |
| Bio-Rad Laboratories, Inc. | 1.4 Billion USD | 99.957% |
| Boston Scientific Corporation | 9.49 Billion USD | 99.994% |
| CONMED Corporation | 991.25 Million USD | 99.939% |
| Edwards Lifesciences Corporation | 694.9 Million USD | 99.913% |
| Paragon 28, Inc. | 112.03 Million USD | 99.463% |
| Glaukos Corporation | 383.73 Million USD | 99.843% |
| Globus Medical, Inc. | 520.4 Million USD | 99.884% |
| Inspire Medical Systems, Inc. | 24.84 Million USD | 97.58% |
| Integer Holdings Corporation | 1.04 Billion USD | 99.942% |
| Medtronic plc | 26.04 Billion USD | 99.998% |
| Nevro Corp. | 221.82 Million USD | 99.729% |
| Owlet, Inc. | 15.21 Million USD | 96.048% |
| Penumbra, Inc. | 234.34 Million USD | 99.743% |
| Vicarious Surgical Inc. | 14.83 Million USD | 95.946% |
| Smith & Nephew plc | 3.08 Billion USD | 99.981% |
| STERIS plc | 3.38 Billion USD | 99.982% |
| Stryker Corporation | 12.99 Billion USD | 99.995% |
| Vapotherm, Inc. | 112.39 Million USD | 99.465% |
| Zimmer Biomet Holdings, Inc. | 5.99 Billion USD | 99.99% |